Caribbean Diabetes Research: 2026 Methodology & Market Guide
Caribbean diabetes prevalence averages 12 percent of adults, reaching 18-20 percent in Barbados, the highest documented rate globally outside the Pacific Islands. This guide covers methodology, country-level data, recruitment approaches, and cost benchmarks for pharma sponsors commissioning Caribbean diabetes research.
Caribbean diabetes prevalence is among the world's highest, making the region strategically important for pharmaceutical research
Caribbean diabetes research is among the most strategically important therapeutic area research conducted in the region. Adult diabetes prevalence across the Caribbean averages 12 percent of adults, with Barbados, Trinidad, and select smaller islands reaching 14-20 percent in some sub-populations. These rates are three to four times higher than United States prevalence and place the Caribbean among the highest diabetes-prevalence regions globally outside the Pacific Islands. The combined population of major Caribbean markets exceeds 40 million people, producing an estimated 4-5 million adults living with diabetes.
Why Caribbean Diabetes Research Is Different
Diabetes research conducted in the Caribbean differs from research in larger pharmaceutical markets in five ways that pharmaceutical sponsors and research vendors need to understand before designing programs.
Disease prevalence is structurally elevated due to genetic, dietary, and lifestyle factors. The Caribbean population includes significant African-ancestry, East Indian-ancestry, and admixed populations, with genetic predisposition to type 2 diabetes that compounds with dietary patterns high in refined carbohydrates and processed foods. The result is the highest documented diabetes prevalence outside the Pacific Islands.
Sub-population prevalence varies meaningfully. East Indian-descent populations in Trinidad and Guyana show diabetes prevalence at 14-18 percent of adults, higher than the regional average. African-descent Caribbean populations average 11-13 percent. Admixed populations vary by country. These differences matter for research design and sample stratification.
Treatment access is uneven. Public-system diabetes patients in most Caribbean countries receive different medication, monitoring frequency, and education than private-system patients. Older oral hypoglycemic agents remain common in public systems while newer agents (GLP-1 receptor agonists, SGLT-2 inhibitors, modern insulins) concentrate in private-system patients with private insurance or out-of-pocket capacity. Research that draws exclusively from one care setting misses critical treatment-decision variance.
Continuous glucose monitoring adoption is uneven and growing. CGM penetration in the Caribbean is dramatically lower than in the United States but growing rapidly, particularly in Puerto Rico, the Dominican Republic, and among Jamaica's private-system patients. Research on CGM adoption, user experience, and integration with insulin therapy is increasingly commissioned.
The diaspora dimension shapes treatment decisions. Caribbean diabetes patients with serious complications or complex management needs frequently consult with US-based endocrinologists, family members in medicine abroad, or travel for specialist care. This shapes the treatment-decision journey in ways that affect research conclusions when only in-country care is studied.
The Caribbean Diabetes Burden by Country
Understanding country-by-country prevalence is essential for designing recruitment that hits realistic targets and producing region-relevant insights.
| Country | Adult Diabetes Prevalence | Approx. Adult Diabetic Population | Notes |
|---|---|---|---|
| Jamaica | 12-13% | 250,000-275,000 | Strong endocrinology specialist concentration in Kingston |
| Trinidad and Tobago | 14-16% (higher in East Indian sub-population) | 175,000-200,000 | EWMSC and Mt Hope major recruitment anchors |
| Dominican Republic | 11-13% | 850,000-1,000,000 | Spanish-language only; largest absolute patient pool |
| Puerto Rico | 16% (US Hispanic high rate) | 400,000-450,000 | US-aligned regulatory, bilingual operations |
| Barbados | 18-20% (highest documented) | 35,000-40,000 | UK-trained physician majority |
| Bahamas | 11-13% | 30,000-35,000 | Concentrated in Nassau |
| Guyana | 14-15% | 80,000-100,000 | East Indian-descent population effect |
| Eastern Caribbean (combined) | 11-14% | 60,000-80,000 | Often researched as regional cluster |
Sources: International Diabetes Federation Atlas, Caribbean Public Health Agency surveillance reports, country-specific Ministry of Health data, IHME Global Burden of Disease.
Combined adult diabetic population across major Caribbean markets: approximately 4-5 million. This is a strategically important patient population for global diabetes pharmaceutical sponsors.
Types of Diabetes Research Programs in the Caribbean
Five major program types cover most pharmaceutical sponsor needs. Programs frequently combine elements from multiple types.
HCP Research
Healthcare professional research on diabetes covers endocrinologists, internal medicine specialists treating diabetes, general practitioners managing the majority of routine diabetes care, and certified diabetes educators where the role exists. Common HCP research designs include in-depth interviews with endocrinologists on prescribing decisions and product perceptions, quantitative HCP surveys on treatment pathway adoption, advisory boards convening regional KOL endocrinologists, and treatment pathway mapping combining HCP and patient input.
Endocrinologist scarcity affects program design. Jamaica has fewer than 50 practicing endocrinologists. Trinidad has fewer. Barbados has approximately 5-8. The Dominican Republic has more, with a Spanish-speaking pool extending to over 100. Puerto Rico has US-comparable specialist density. Programs requiring large endocrinologist samples need careful country mix planning. See also: Caribbean HCP Research Methodology.
Patient Research
Patient-facing diabetes research is the largest category by volume in Caribbean pharma research. High prevalence enables substantial sample sizes from focused recruitment. Common patient research designs include treatment satisfaction studies for specific medication classes, adherence and persistence research, insulin therapy initiation studies, GLP-1 receptor agonist user experience, continuous glucose monitoring adoption and use, diabetic complications experience research (retinopathy, neuropathy, nephropathy), quality of life measurement, and treatment journey mapping. See also: Caribbean Patient Recruitment Methodology.
Pharmacy and Retail Audit
Diabetes-specific pharmacy audits measure distribution, pricing accuracy, availability of specific medication classes, OTC supplement availability for diabetes (chromium, cinnamon, alpha-lipoic acid, etc.), and pharmacist counseling quality on diabetes management. Combined with diabetes patient research, retail audits map the full commercial channel for diabetes therapeutics.
OTC and Device Research
The OTC and device category for diabetes covers glucose meters and test strips, CGM systems, insulin pens and pen needles, diabetes supplements, and increasingly, smartphone-connected diabetes management tools. Research on these products includes concept testing, usability studies, adoption barrier identification, and channel preference research.
Real-World Evidence and Outcomes Research
Outcomes research that follows diabetes patients longitudinally to measure real-world effectiveness, adherence patterns, and outcomes is growing in Caribbean research. These programs typically require 6-12 month follow-up periods and clinical data integration that requires careful ethics committee design.
Therapeutic Approaches Routinely Studied
Insulin Therapy
Insulin remains foundational for type 1 diabetes and advanced type 2 diabetes management across the Caribbean. Research areas include insulin initiation timing decisions, basal vs basal-bolus regimen selection, insulin pen vs syringe preference and technique, insulin storage challenges in tropical climates, and cost and access barriers in public vs private healthcare. Long-acting analog insulins (insulin glargine, degludec) and rapid-acting analogs are well-established in Caribbean private practice. Older insulin formulations remain common in public systems due to procurement decisions.
GLP-1 Receptor Agonists
GLP-1 receptor agonist research has accelerated dramatically in the Caribbean over the past 24 months. Research areas include awareness and adoption among Caribbean endocrinologists, patient experience with weekly injectable formulations (semaglutide, dulaglutide), oral semaglutide adoption patterns, cost as adoption barrier in markets with limited insurance coverage, and cross-utilization for weight management vs diabetes. Caribbean GLP-1 research generates particular interest because the regional patient population has high BMI prevalence alongside diabetes, making the dual indication particularly relevant.
SGLT-2 Inhibitors
SGLT-2 inhibitor research is expanding given the class's cardiovascular and renal protective effects beyond glucose control. Research areas include cardiology vs endocrinology prescribing dynamics, patient awareness of cardiovascular benefits, side effect tolerability in Caribbean populations, and combination therapy patterns with metformin and other agents.
Continuous Glucose Monitoring
CGM adoption is uneven across the Caribbean but growing rapidly. Research areas include adoption rates by country, payer status, and patient profile; user experience with current sensor systems; integration with insulin therapy decisions; cost as adoption barrier; and healthcare provider training and confidence in CGM data interpretation. Puerto Rico shows the highest Caribbean CGM penetration given US insurance frameworks. Dominican Republic shows accelerating adoption through private healthcare. Other markets remain at lower penetration with growth opportunity.
Combination Therapies
Fixed-dose combinations including SGLT-2 inhibitor plus DPP-4 inhibitor, GLP-1 plus insulin combinations, and triple-class oral combinations are increasingly studied as complexity of Caribbean diabetes management increases.
Specific Methodologies for Caribbean Diabetes Research
Patient Journey Mapping
The most insight-dense methodology for understanding Caribbean diabetes care. Programs combine 25-40 patient IDIs across major countries, HCP perspective from 10-15 endocrinologists, and quantitative validation surveys to build country-specific care journeys from diagnosis through complication management. Effective Caribbean diabetes journey research stratifies by country, disease duration (newly diagnosed, established, with complications), care setting (public vs private), insulin status, and treatment complexity.
Treatment Satisfaction and Adherence Research
Standardized instruments (Treatment Satisfaction Questionnaire for Medication, Morisky Medication Adherence Scale) are deployable across Caribbean diabetes patients with appropriate cultural adaptation. Sample sizes of 200-400 patients per country are achievable in 6-10 weeks.
Adherence Mapping with Pharmacy Refill Data
Where pharmacy partnerships permit, prescription refill pattern analysis provides objective adherence measurement to complement self-reported adherence. Particularly useful in chain pharmacy markets (Jamaica's Fontana, Trinidad's Carlton, Puerto Rico's Walgreens).
Real-World Evidence Studies
Longitudinal patient cohorts followed 6-12 months produce data that single-point research cannot. Common designs include treatment switching cohorts (patients initiating GLP-1 or SGLT-2 from prior regimens), insulin initiation cohorts, CGM adoption cohorts, and complication onset and management cohorts.
Country-Specific Considerations
Sample Sizes Realistic for Caribbean Diabetes Studies
| Study Type | Achievable Single-Country Sample | Pan-Caribbean Sample |
|---|---|---|
| Endocrinologist IDIs | 8-15 (varies by country size) | 35-60 |
| Internal medicine / GP IDIs | 15-25 | 60-100 |
| Patient IDIs, type 2 diabetes | 25-50 | 100-200 |
| Patient IDIs, insulin users | 15-30 | 60-120 |
| Patient IDIs, CGM users | 10-25 (varies sharply by country) | 40-100 |
| Quantitative patient survey | 300-600 | 1,200-2,500 |
| Quantitative HCP survey | 80-200 specialists | 300-600 |
| Pharmacy retail audit | 60-150 stores | 300-700 |
Larger samples are achievable in the Dominican Republic and Puerto Rico due to population scale.
Recruitment Channels for Caribbean Diabetes Research
Effective Caribbean diabetes patient recruitment uses several channels in combination.
- HCP-mediated referral through cooperating endocrinologists and internists. Particularly effective because diabetes is a chronic condition with regular HCP touchpoints.
- Pharmacy-based screening at the point of diabetes medication pickup. High-yield for type 2 patients on oral therapy or basal insulin.
- Diabetes association partnerships. The Diabetes Association of Jamaica, Diabetes Association of Trinidad and Tobago, Sociedad Dominicana de Endocrinología y Nutrición, and country-specific associations support recruitment for appropriately-framed research.
- Database recall of prior research participants. Hope Research Group maintains a Caribbean diabetes patient panel with appropriate consent.
- Specialty clinic partnerships with diabetes clinics at major academic medical centers and private specialty practices.
- Community health screening events where appropriate for research that benefits from population-based recruitment.
What Caribbean Diabetes Research Costs in 2026
| Program Type | Sample Size | Typical Cost (USD) |
|---|---|---|
| Endocrinologist IDI study, single country | 12-15 | USD 40,000 - 80,000 |
| Endocrinologist IDI study, pan-Caribbean | 30-45 | USD 100,000 - 200,000 |
| Type 2 diabetes patient qualitative | 25-40 patients | USD 50,000 - 90,000 |
| Diabetes patient quantitative survey | n=400-600 | USD 70,000 - 140,000 |
| GLP-1 user experience study | 20-30 GLP-1 users | USD 55,000 - 100,000 |
| CGM adoption multi-country | 50-80 CGM users | USD 90,000 - 180,000 |
| Diabetes pharmacy audit, single country | 100-200 stores | USD 40,000 - 80,000 |
| Longitudinal diabetes cohort, 6 months | 60-120 patients | USD 130,000 - 260,000 |
| Real-world evidence study, 12 months | 100-200 patients | USD 180,000 - 380,000 |
| Pan-Caribbean diabetes patient journey | 80-150 patients across 4-5 countries | USD 180,000 - 400,000 |
Ranges include program design, instrument development, IRB submission where required, recruitment, fieldwork, transcription and translation, quality control, and reporting.
Common Mistakes in Caribbean Diabetes Research
The errors that recur across diabetes programs designed by firms without Caribbean operational experience:
- Importing US sample size assumptions. US diabetes studies routinely recruit 600-1,000 patients per arm. Caribbean equivalents require careful sample size justification based on prevalence and accessible patient pools.
- Ignoring sub-population variation. Pooling Trinidad East Indian, Jamaican African-descent, and Dominican admixed populations into a single Caribbean sample loses important variance.
- Assuming uniform CGM access. Programs that assume Caribbean CGM penetration matches US baseline produce unusable comparison data.
- Single-language regional studies. Pan-Caribbean diabetes research that operates only in English misses the Dominican Republic patient pool entirely.
- Underestimating ethics approval timelines. Patient research touching PHI requires 60-90 days for ethics review in most Caribbean markets.
- Recruiting from a single care setting. Public-only or private-only recruitment misses critical treatment-decision variance.
- Ignoring diaspora consultation patterns. Caribbean diabetes patients with complications often have US or Canadian care relationships that shape decisions.
- Honoraria scales inappropriate to local context. Over-payment raises sponsor compliance concerns; under-payment fails recruitment.
How to Choose a Caribbean Diabetes Research Vendor
The selection markers that distinguish capable diabetes research firms from generalist research companies. Ask for:
- Years of diabetes-specific research experience in the Caribbean
- Endocrinologist and patient panel size by country
- Diabetes association partnerships with specific named organizations
- Documented therapeutic area work in GLP-1, SGLT-2, insulin, CGM, or other relevant classes
- Ethics committee submission history with diabetes patient research specifically
- References from comparable pharmaceutical sponsors in diabetes therapeutic area
- Sample reports from comparable Caribbean diabetes programs (appropriately de-identified)
- Bilingual capability for pan-Caribbean studies including Dominican Republic and Puerto Rico
Vendors that respond with general capability statements should be approached with caution. Diabetes research operational expertise takes years to develop.
Get a Caribbean diabetes research proposal from Hope Research Group
40 years of regional pharma research, endocrinologist and patient panels across major Caribbean markets, diabetes therapeutic area depth.
Request a ProposalFrequently Asked Questions
How quickly can you recruit Caribbean diabetes patients?
For high-prevalence type 2 diabetes patients, qualitative recruitment of 25-30 patients typically completes within 4-6 weeks per country. Quantitative samples of n=400-600 require 8-12 weeks. Specialty sub-populations (insulin users, CGM users, GLP-1 users) extend timelines proportionally.
Can you research specific diabetes medication classes?
Yes. Hope Research Group has conducted research across insulin (including modern analogs), GLP-1 receptor agonists, SGLT-2 inhibitors, DPP-4 inhibitors, metformin, sulfonylureas, and combination therapies. CGM and insulin pump research has expanded in recent years given accelerating adoption.
How do you handle Spanish-language diabetes research?
Spanish-language diabetes research in the Dominican Republic and Puerto Rico is a routine service. Programs combining English-speaking Caribbean and Spanish-speaking Caribbean use parallel local field teams with central methodology coordination, translated and back-translated instruments, and culturally-equivalent question wording.
What's distinctive about Caribbean diabetes from a research perspective?
Three things: prevalence is structurally higher than in Western markets; the East Indian-descent populations in Trinidad and Guyana show particularly elevated rates with potentially different treatment response patterns; and treatment access varies dramatically between public and private healthcare systems within the same country.
Do you provide GCP-compliant clinical research services?
No. Hope Research Group provides diabetes market research and patient insights work, not GCP-regulated clinical trials. Diabetes clinical trials require dedicated CRO infrastructure. We work alongside CROs where market research complements clinical development programs.
Can you support real-world evidence studies in diabetes?
Yes for observational and longitudinal patient cohort research, treatment switching studies, adherence pattern research, and outcomes research that does not require GCP compliance. Programs requiring formal regulatory submission for label expansion or post-marketing commitments require GCP-compliant CRO partnership.